FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

FORCE Blog

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 7,413 other subscribers

Archives

Posts Tagged ‘RAD51C’

October 25, 2016

Guest Blog: Genetic Variants of Uncertain Significance

by Nancy Ledbetter Early on in my genetics nursing career, I remember explaining the possibility of a variant of uncertain significance (VUS) to a patient, who laughed and said, “Variant of uncertain significance? That sounds like something out of Monty Python!” I had to admit she had a good point. It sounds like a ridiculous … + read more

June 2, 2016

Results from the KNOW MORE Survey: Genetic Counseling and Testing in Women with Different Types of Ovarian Cancer

KNOW MORE is a campaign designed by FORCE to help women diagnosed with ovarian, fallopian tube, or primary peritoneal cancers make informed decisions about genetic counseling and testing for inherited gene mutations. We kicked off the effort by launching a brief survey to better understand how women with ovarian and related cancers make decisions about genetic … + read more

May 27, 2016

Blog: What Do the New Guidelines from the National Comprehensive Cancer Network Mean For You?

by Lisa Rezende, PhD People with hereditary cancer face many decisions, such as whether or not to have genetic testing, choosing the best type and frequency of cancer screening, and whether or not to manage cancer risk through surgery. Health care providers look to national guidelines to give their patients advice as they make these … + read more

May 19, 2016

Updates in Research on Treating Hereditary Cancers

Note: This post which was originally published 08/4/15 was just updated on 05/19/16. In December 2014, the FDA approved the first targeted therapy for people with BRCA mutations. Lynparza, a type of medication known as a PARP inhibitor, was approved for women with a BRCA mutation to treat advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered